Cision PR Newswire, Author at World Lifestyler

No Result

View All Result

WORLD LIFESTYLER

No Result

View All Result

Home Author

Cision PR Newswire

Press Releases - Lifestyle

Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP

June 7, 2026

Press Releases

VolitionRx Announces Pricing of $4.6 Million Public Offering

June 7, 2026

Press Releases - Lifestyle

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

June 7, 2026

Press Releases - Lifestyle

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

June 7, 2026

Press Releases - Lifestyle

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

June 7, 2026

Press Releases - Lifestyle

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

June 7, 2026

Press Releases - Lifestyle

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

June 7, 2026

Press Releases - Lifestyle

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Press Releases - Lifestyle

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

June 7, 2026

Page 790 of 3702 Prev 1 … 789 790 791 … 3,702 Next

No Result

View All Result

Home

Cision PR Newswire

Sportradar Group AG (SRAD) Investors: July 17, 2026, Deadline in Securities Fraud Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP

VolitionRx Announces Pricing of $4.6 Million Public Offering

Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026

Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Lipid-Lowering Medications Demonstrate Cardiometabolic Benefits in Populations with High-Risk Diabetes

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges Badger Meter, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Recommended

Huawei Li Peng: Accelerating Towards the Agentic Internet Era with 5G-A and AI

GeneDx Holdings Corp. Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – WGS

Popular News

Boeing: Global Commercial Fleet Will Top 50,000 Airplanes in 20 Years as Passenger Traffic Doubles

Duke Energy Carolinas reaches agreement with North Carolina Public Staff and other stakeholders to deliver a lower-cost path to power North Carolina’s future

Boeing Forecasts $4.9 Trillion Commercial Aviation Support and Services Market and Demand for more than 2.4 Million New Aviation Personnel Over 20 Years

Co-Founder William Hoffmann Retires from Grotefeld Hoffmann & Gordon LLP

Gulf South Business Roundtable Convenes National Leaders to Advance America’s Energy and Industrial Future

Connect with us

About & Contact

Explore Content

Legal & Privacy

Tiny Media Brands